Help us find a treatment for COVID–19...
Background: What is COVID–19?
COVID–19 (CoronaVirus Disease–2019) is a disease caused by a new strain of Coronavirus – the SARS–CoV–2 (Severe Acute Respiratory Syndrome–CoronaVirus–2). Adult patients with COVID–19 develop a variety of symptoms ranging from mild/moderate (fever, dry cough, headache and muscular pain) to severe (pneumonia, and breathing difficulties associated with severe acute respiratory syndrome) or, in some instances, death. In children under 5 years of age, SARS-CoV-2 can cause a vasculitis syndrome known as Kawasaki Disease – a paediatric disease characterized by the inflammation of blood vessels (e.g. coronary arteries) and other symptoms including fever, red eyes and skin rashes of palms and soles.
For an elegant visual animation on the effects of SARS–CoV–2 on the human body, take a look at the beautiful video below by Random42 Scientific Communications!
Impact of COVID–19
The outbreak of COVID–19 was declared a Public Health Emergency of International Concern on January 30th 2020 and a Pandemic on March 11th 2020. As of September 3rd 2020, according to the World Health Organization (WHO), over 870,000 people have succumbed to complications associated with COVID–19, worldwide. This is, likely, a gross underestimate of the true number of COVID–19–related deaths, which is expected to increase steadily in the coming months, before an effective vaccine or antiviral treatment becomes available.
Our Team: Who Are We?
We are a team of dedicated young scientists, medical doctors and financial analysts with extensive experience with drug discovery. Our company (PrimerGen Ltd.) is based in Europe. Our fiscal identification number is 516076620.
Our Research: What Do We Do?
At PrimerGen Ltd, we are working hard to find a novel antiviral treatment for COVID–19. We are a very small biotech company composed of a team of scientists, medical doctors and financial analysts with extensive experience in R&D. We are currently looking for seed funding to support important new research on a novel antiviral treatment. Specifically, we want to test whether old off-patent drugs already approved for human use can be repurposed for the treatment of COVID–19. Our team has extensive scientific experience with drug discovery and is committed to assessing the potential of these drugs in the treatment of COVID–19.
Our Strategy: What is our plan?
Repurposing off-patent approved medications for the treatment of COVID–19
There is, currently, a pressing need for an effective treatment for COVID–19. We propose to evaluate the antiviral therapeutic potential of a clinically approved drugs against SARS-CoV-2 in vitro and elucidate the antiviral mechanism(s)-of-action of this drug.
Developing new drugs is a time-consuming and costly process. The vast majority of compounds fail to advance past phase I clinical trials, typically owing to their poor toxicity profiles. A tested-and-tried alternative to developing novel treatments is to repurpose old approved medications, with acceptable toxicity profiles, for alternative purposes. The latter strategy greatly expedites the invariably lengthy process of drug development, while simultaneously considerably reducing the overall costs associated with drug discovery.
Do not under any circumstance take the information published herein as medical advice. We do not recommend you (or anyone) taking any of the medication listed in this website without prior consultation with your Physician (Medical Doctor). Taking the above-mentioned medications without medical supervision may cause serious harm or even death. Under no circumstances is PrimerGen Ltd. (or its members) to be held responsible for any consequence resulting from administration of the above-described medications
Sponsor us: We Need Your Help!
Help us develop an efficacious treatment for COVID-19! Every little bit helps.
Thank you from all of us at PrimerGen Ltd :)
Bruno Fonseca, Ph.D.
Bruno Moraes, M.Sc.
Raul Afonso, C.F.A.
Inês Cabrita, Ph.D.
Luís Rodrigues, M.D.
If you want to learn more about what we do, visit our website at https://primergen.group or contact us at [email redacted]up